Profile Image

Conjoint Professor Stephen Ackland

Conjoint Professor

Faculty of Health and Medicine (Pharmacy and Experimental Pharmacology)

Career Summary

Biography

Prof. Stephen Ackland is Staff Specialist, Department of Medical Oncology, Calvary Mater Newcastle Hospital and Conjoint Professor, Faculty of Health, University of Newcastle. He is the Director, Hunter Cancer Research Alliance; Director, University of Newcastle Priority Research Centre for Cancer; Director of Clinical Cancer Research Network HNE Health; Co-director of Hunter Medical Research Institute Cancer Research Program. He has played a key role in organisation, harmonisation and enhancements of translational and clinical research locally, on a state basis and nationally. He is Editor-in-Chief, Asia-Pacific Journal of Clinical Oncology. He is an inaugural member of the PRIMe consortium (Pharmacogenomics Research towards Individualised Medicine), a NSW Cancer Council-funded collaboration of 8 NSW hospitals and research institutes with the aim of facilitating cancer pharmacogenomics research in NSW.

Committee appointments include: Honorary Secretary, Medical Oncology Group of Australia, 1997-2000; Chairman, Medical Oncology Group of Australia, 1999-2000. Chair, Specialist Advisory Committee in Medical Oncology, RACP, 1999-2000; AMWAC Committee on Medical Oncology 1999-2001; President, Clinical Oncological Society of Australia 2004-2005; Director, Australian & New Zealand Breast Cancer Trials Group, 2007-; Director, NSW Cancer Council, 2006-2014.

He is the author of over 90 original publications in peer-reviewed journals and first author on 18 of these. He was co-owner of 2 patents. He has been investigator on 25 grants totaling $10.9m, including lead investigator on 8 grants valued at approx $4m. He has had extensive involvement in cancer clinical trials, clinical pharmacokinetics and pre-clinical pharmacology of anticancer drugs and combinations. He has been the principal investigator on two Australian multi-institutional randomised controlled trials run through cancer cooperative trials groups, and principal investigator on a number of phase I & II trials. He is/has been a member of the trial management committee of a number of cancer cooperative trials groups, undertaking multi-institutional trials in breast and GI cancer.

Research Expertise
Basic and clinical pharmacology of anticancer drugs, including drug measurement, pharmacokinetics pharmacodynamics, and relevant genetics/genomics. Clinical trials in cancer mainly medical oncology.

Teaching Expertise
Teaches medical nursing and allied health students and postgraduates in basic and clinical oncology. Also science students in pharmacology

Administrative Expertise
Director of Medical Oncology 2001-2005. Manages the Medical Oncology research program (9 staff, clinical and lab).Chair of HMRI Cancer Research Program 2003 -present. President of Clinical Oncological Soc of Australia 2004 and 2005. Chairman, Medical Oncology Group of Australia 1999 and 2000. Board member, TheraPPy Pty Ltd 2004-2006. Board member Cancer Council NSW 2006-2009. Member, International Affairs Committee, Am Soc of Clin Oncol, 1998-2000 and 2006-2009 


Qualifications

  • Bachelor of Medicine & Surgery, University of Melbourne

Keywords

  • Clinical Trials
  • Medical Oncology
  • Medicine
  • Pharmacogenomics
  • Pharmacokinetics
  • Pharmacology

Fields of Research

CodeDescriptionPercentage
110399Clinical Sciences not elsewhere classified35
111599Pharmacology and Pharmaceutical Sciences not elsewhere classified35
111299Oncology and Carcinogenesis not elsewhere classified30

Professional Experience

Academic appointment

DatesTitleOrganisation / Department
1/07/2007 - DirectorANZ Breast Cancer Trials Group
Australia
1/09/2006 - DirectorCancer Council NSW
1/01/2005 - Editorial Board - Asia Pacific Journal of Clinical OncologyAsia Pacific Journal of Clinical Oncology
Japan
1/09/2004 - EditorAsia Pacific Journal of Clinical Oncology
Australia
1/06/1984 - 1/06/1987Fellow in Haematology and OncologyUniversity of Chicago
Haematology and Medical Oncology
United States

Membership

DatesTitleOrganisation / Department
1/09/2006 - 1/09/2009MembershipInternational Affairs Committee
United States
1/01/2006 - 1/12/2008Membership - ASCO International Affairs CommitteeASCO International Affairs Committee
Australia
1/01/2004 - 1/01/2006PresidentClinical Oncological Society of Australia
1/01/2004 - 31/12/2006Membership - Clinical Oncological Society of AustraliaClinical Oncological Society of Australia
1/01/1999 - 1/01/2001ChairmanMedical Oncology Group of Australia
Australia
1/01/1997 - 1/12/1999Membership - ASCO International Affairs CommitteeASCO International Affairs Committee
Australia
1/01/1994 - Membership -Scientific Advisory CommitteeAustralasian GI Trials Group
Australia

Professional appointment

DatesTitleOrganisation / Department
1/03/2007 - Area Director of Clinical Cancer ResearchHunter New England Health
Clinical Cancer Research- Oncology
Australia
1/08/1995 - Senior staff specialistNewcastle Mater Misericordiae Hospital
Medical Oncology
Australia
1/08/1987 - 1/08/1995Staff SpecialistNewcastle Mater Misericordiae Hospital
Medical Oncology
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

YearCitationAltmetricsLink
2003Ackland S, Beale P, Godefridus J, 'Thymidylate synhase inhibitors', Cancer chemotherapy and Biological response modifiers, Elsevier BV, netherlands 1-28 (2003) [B2]
CitationsScopus - 1

Journal article (93 outputs)

YearCitationAltmetricsLink
2014Yip D, Zalcberg J, Ackland S, Barbour AP, Desai J, Fox S, et al., 'Controversies in the management of gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, 10 216-227 (2014) [C1]

Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primary tumors. The Consensus approaches to best practice management of gastrointestinal stromal tumors, published in this journal in 2008, provided guidance for the management of GIST to both clinicians and regulatory authorities. Since then, clinical trials have demonstrated the benefit of adjuvant imatinib in high-risk patients, and mature data from advanced GIST studies suggest that a small but significant proportion of patients with advanced disease can achieve long-term benefit with ongoing imatinib treatment. Other evolving management strategies include the controversial use of palliative or debulking surgery to improve outcomes in advanced GIST and the development of promising new multikinase inhibitors, such as regorafenib, which has established benefit in the third-line setting. This review provides an update of recent developments in GIST management and discusses new controversies that these advances have generated. © 2014 Wiley Publishing Asia Pty Ltd.

DOI10.1111/ajco.12187
CitationsScopus - 3Web of Science - 1
2014Yip D, Zalcberg J, Fox S, Mcarthur G, Desai J, Ackland S, et al., 'Controversies in the management of gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, 10 216-227 (2014)
DOI10.1111/ajco.12187
2013Ackland S, Goldstein D, McJannett M, 'Forty years of COSA - Contributions to oncology teaching and research', Cancer Forum, 37 238-242 (2013) [C2]
2013Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, et al., 'Current opinion on optimal treatment for colorectal cancer', EXPERT REVIEW OF ANTICANCER THERAPY, 13 597-611 (2013) [C1]
DOI10.1586/ERA.13.37Author URL
CitationsScopus - 7Web of Science - 9
2013Ackland S, Fukuda Y, '2012: Year in Review - from dragons to snakes', Asia-Pacific Journal of Clinical Oncology, 9 1-1 (2013) [C3]
DOI10.1111/ajco.12065
2012Goldstein D, Spry N, Cummins MM, Brown C, Van Hazel GA, Carroll S, et al., 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106 61-69 (2012) [C1]
CitationsScopus - 4Web of Science - 4
2012Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al., 'Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04', Journal of Clinical Oncology, 30 3827-3833 (2012) [C1]
CitationsScopus - 92Web of Science - 81
2012Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, et al., 'Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C', ANNALS OF ONCOLOGY, 23 1531-1536 (2012) [C1]
DOI10.1093/annonc/mdr488Author URL
CitationsScopus - 32Web of Science - 32
2012Zdenkowski N, Chen S, Van Der Westhuizen A, Ackland S, 'Curative strategies for liver metastases from colorectal cancer: A review', Oncologist, 17 201-211 (2012) [C1]
CitationsScopus - 10Web of Science - 8
2012Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, Sakoff JA, 'Predicting 5-Fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length - A multivariate analysis', British Journal of Cancer, 107 1525-1533 (2012) [C1]
CitationsScopus - 3Web of Science - 5
Co-authorsJennette Sakoff, Lisa Lincz
2012Ackland S, Fukuda Y, '2011: Year in review - From rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2012) [C3]
2011Garg MB, Sakoff JA, Ackland S, 'A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879 2201-2205 (2011) [C1]
CitationsScopus - 5Web of Science - 5
Co-authorsJennette Sakoff
2011Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, et al., 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129 467-476 (2011) [C1]
DOI10.1007/s10549-011-1471-9
CitationsScopus - 1Web of Science - 1
2011Ackland S, Fukuda Y, '2011: Year in Review - from rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2011)
DOI10.1111/j.1743-7563.2012.01538.x
2011Ackland S, 'Cancer in Australia: A model for other Asia-Pacific countries', Asia-Pacific Journal of Clinical Oncology, 7 323-324 (2011) [C3]
DOI10.1111/j.1743-7563.2011.01507.x
2011Agrez M, Garg M, Dorahy D, Ackland S, 'Synergistic anti-tumor effect of cisplatin when combined with an anti-src kinase integrin-based peptide', Journal of Cancer Therapy, 2 295-301 (2011) [C1]
2011Vilain RE, Dudding TE, Braye SG, Groombridge C, Meldrum C, Spigelman AD, et al., 'Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome?', Clinical Genetics, 79 554-560 (2011) [C3]
DOI10.1111/j.1399-0004.2010.01489.x
CitationsScopus - 4Web of Science - 2
Co-authorsLeonie Ashman, Rodney Scott
2011Garg MB, Ackland S, 'Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect', Cancer Chemotherapy and Pharmacology, 67 963-966 (2011) [C1]
CitationsScopus - 6Web of Science - 5
2011Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland S, Van Hazel G, et al., 'Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 67 519-525 (2011) [C1]
CitationsScopus - 2Web of Science - 3
2011Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al., 'Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)', JOURNAL OF CLINICAL ONCOLOGY, 29 (2011) [E3]
Author URL
2011Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland S, Fitzharris B, et al., 'Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer', Journal of Clinical Oncology, 29 4498-4504 (2011) [C1]
CitationsScopus - 37Web of Science - 29
Co-authorsJohn Forbes
2010Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, Van Hazel GA, et al., 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study', Journal of Clinical Oncology, 28 3191-3198 (2010) [C1]
DOI10.1200/JCO.2009.27.7723
CitationsScopus - 142Web of Science - 125
2010De Bock CE, Garg ML, Scott NM, Sakoff JA, Scorgie FE, Ackland S, Lincz L, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, 1-8 (2010) [C1]
DOI10.1038/tpj.2010.43
CitationsScopus - 7Web of Science - 7
Co-authorsLisa Lincz, Manohar Garg, Jennette Sakoff
2009Ackland S, Bull JM, Boyle FM, 'Nab-Paclitaxel: A bright new sparc in taxane therapy of cancer', Asia-Pacific Journal of Clinical Oncology, 5 147-150 (2009) [C1]
DOI10.1111/j.1743-7563.2009.01233.x
2009Ackland S, 'Molecular biomarkers in non-small cell lung cancer: Pointing the way to better outcomes from treatment', Asia-Pacific Journal of Clinical Oncology, 5 213-214 (2009) [C3]
DOI10.1111/j.1743-7563.2009.01260.x
2009Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, et al., 'Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer', ONCOLOGY, 77 113-119 (2009) [C1]
DOI10.1159/000229787Author URL
CitationsScopus - 85Web of Science - 73
2008Ackland S, Tracey E, 'Cancer registries: Their role in health care delivery in the Asia-Pacific region', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 4 71-74 (2008) [C3]
DOI10.1111/j.1743-7563.2008.00160.xAuthor URL
CitationsScopus - 1Web of Science - 1
2008Vilain RE, Ackland S, 'Gastrointestinal stromal tumors - A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?', Asia-Pacific Journal of Clinical Oncology, 4 185-187 (2008) [C3]
2008Hill TA, Stewart SG, Gordon CP, Ackland SR, Gilbert J, Sauer B, et al., 'Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition', ChemMedChem, 3 1878-1892 (2008) [C1]
DOI10.1002/cmdc.200800192
CitationsScopus - 32Web of Science - 32
Co-authorsAdam Mccluskey, Jennette Sakoff
2007Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity', Bioorganic and Medicinal Chemistry Letters, 17 3392-3397 (2007) [C1]
DOI10.1016/j.bmcl.2007.03.093
CitationsScopus - 49Web of Science - 45
Co-authorsJennette Sakoff, Adam Mccluskey
2007Hill TA, Stewart SG, Ackland S, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation', Bioorganic and Medicinal Chemistry, 15 6126-6134 (2007) [C1]
DOI10.1016/j.bmc.2007.06.034
CitationsScopus - 51Web of Science - 49
Co-authorsAdam Mccluskey, Jennette Sakoff
2007Stewart SG, Hill TA, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity', Bioorganic and Medicinal Chemistry, 15 7301-7310 (2007) [C1]
DOI10.1016/j.bmc.2007.08.028
CitationsScopus - 33Web of Science - 27
Co-authorsJennette Sakoff, Adam Mccluskey
2007Temmink OH, Hoebe EK, Van Der Born K, Ackland S, Fukushima M, Peters GJ, 'Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells', British Journal of Cancer, 96 231-240 (2007) [C1]
DOI10.1038/sj.bjc.6603549
CitationsScopus - 20Web of Science - 17
2007Lincz L, Scorgie FE, Garg MB, Ackland S, 'Identification of a novel single nucleotide polymorphism in the second tandem repeat sequence of the thymidylate synthase 2R allele', International Journal of Cancer, 120 1930-1934 (2007) [C1]
DOI10.1002/ijc.22568
CitationsScopus - 29Web of Science - 26
Co-authorsLisa Lincz
2007Lincz L, Scorgie FE, Garg ML, Ackland S, 'Reply to the letter to the editor 'Classification of thymidylate synthase gene enhancer region polymorphisms'', International Journal of Cancer, 121 2581-2582 (2007) [C3]
DOI10.1002/ijc.22987
Co-authorsLisa Lincz, Manohar Garg
2007Young JM, Leong DC, Armstrong K, O'Connell D, Armstrong BK, Spigelman AD, et al., 'Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study', Medical Journal of Australia, 186 292-295 (2007) [C1]
CitationsScopus - 21Web of Science - 19
2007Carrington C, Carlton J, Ackland S, 'Preventing chemotherapy errors: Implementing system changes', Asia-Pacific Journal of Clinical Oncology, 3 57-58 (2007) [C3]
2007Davis AJ, Brew S, Gebski VJ, Lewis CR, Moylan E, Parnis FX, Ackland S, 'Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 3 37-43 (2007) [C1]
DOI10.1111/j.1743-7563.2006.00083.x
CitationsScopus - 5Web of Science - 3
2007Findlay M, Sharples K, Riley GA, Simpson A, Ackland S, Hall K, et al., 'Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer', Asia-Pacific Journal of Clinical Oncology, 3 99-105 (2007) [C1]
DOI10.1111/j.1743-7563.2007.00095.x
CitationsScopus - 5Web of Science - 5
2006Goldstein D, Ackland S, Bell DR, Olver IN, Davis ID, Rosenthal MA, et al., 'Phase II study of vinflunine in patients with metastatic renal cell carcinoma', Investigational New Drugs, 24 429-434 (2006) [C1]
DOI10.1007/s10637-006-6437-0
CitationsScopus - 15Web of Science - 9
2006Wong M, Balleine RL, Blair EYL, McLachlan AJ, Ackland S, Garg M, et al., 'Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer', Journal of Clinical Oncology, 24 2448-2455 (2006) [C1]
DOI10.1200/JCO.2005.02.1295
CitationsScopus - 41Web of Science - 37
2006Ackland S, 'Cervical carcinoma: A common and preventable problem in developing countries (Editorial)', Asia-Pacific Journal of Clinical Oncology, 2 69-70 (2006) [C3]
CitationsScopus - 1
2006Ackland S, Clarke SJ, Beale P, Peters GJ, 'Thymidylate synthase inhibitors', Update on Cancer Therapeutics, 1 403-427 (2006) [C1]
DOI10.1016/j.uct.2006.09.001
CitationsScopus - 9
2005Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, et al., 'A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer', British Journal of Cancer, 93 1236-1243 (2005) [C1]
DOI10.1038/sj.bjc.6602841
CitationsScopus - 31Web of Science - 26
2005Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al., 'Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial', Lancet Oncology, 6 659-668 (2005) [C1]
DOI10.1016/s1470-2045(05)70288-6
CitationsScopus - 465Web of Science - 392
2004Lincz L, Scorgie F, Sakoff J, Fagan K, Ackland S, Enno A, 'Telomere length predicts neutrophil recovery in absence of G-CSF after autologous peripheral blood stem cell transplantation', Bone Marrow Transplant, 34 439-445 (2004) [C1]
DOI10.1038/sj.bmt.1704607
CitationsScopus - 3Web of Science - 3
Co-authorsLisa Lincz, Jennette Sakoff
2004Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, et al., 'Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients', Clinical and Experimental Pharmacology and Physiology, 31 677-682 (2004) [C1]
DOI10.1111/j.1440-1681.2004.03065.x
CitationsScopus - 8Web of Science - 8
2004Sakoff JA, Howitt IJ, Ackland S, McCluskey A, 'Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition', Cancer Chemotherapy and Pharmacology, 53 225-232 (2004) [C1]
DOI10.1007/s00280-003-0730-9
CitationsScopus - 8Web of Science - 7
Co-authorsAdam Mccluskey, Jennette Sakoff
2004O'Brien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al., 'Reduced cardiotoxicity and comparable efficacy in a phase 3 trial of pegylated liposomal doxorubicine HCI (CAELYX / Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer', Annals of Oncology, 15 440-449 (2004) [C1]
DOI10.1093/annonc/mdh097
CitationsScopus - 542Web of Science - 474
2003Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31 68-79 (2003) [C1]
DOI10.1016/S0045-2068(02)00524-2
CitationsScopus - 72Web of Science - 61
Co-authorsJennette Sakoff, Adam Mccluskey, Michael Bowyer
2003Denham J, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lam D, et al., 'Relapse patterns after chemo-radiation for carcinoma of the oesophagus', Clinical Oncology, 15 98-108 (2003) [C1]
DOI10.1053/clon.2003.0212
CitationsScopus - 34Web of Science - 30
Co-authorsAllison Steigler
2002Sakoff J, Ackland S, Baldwin ML, Atherton MA, McCluskey A, 'Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues', Investigational New Drugs, 20 1-11 (2002) [C1]
CitationsScopus - 61Web of Science - 53
Co-authorsMirella Atherton, Jennette Sakoff, Adam Mccluskey
2002Ackland SP, Clarke SJ, Beale P, Peters GJ, 'Thymidylate synthase inhibitors.', Cancer chemotherapy and biological response modifiers, 20 1-36 (2002)
CitationsScopus - 7
2002Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Milward MJ, Ackland S, 'Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na¿ve patients with advanced non-small-cell lung cancer', Annals of Oncology, 13 737-741 (2002) [C1]
CitationsWeb of Science - 72
2002Rischin D, Ackland S, Smith J, Garg MB, Clarke SJ, Millward MJ, et al., 'Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with G-CSF but not with prophylactic antibiotics', Annals of Oncology, 13 1810-1818 (2002) [C1]
CitationsScopus - 11Web of Science - 11
2002McCluskey A, Ackland S, Gardiner E, Walkom CC, Sakoff J, 'The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16 291-303 (2002) [C1]
CitationsScopus - 27Web of Science - 22
Co-authorsJennette Sakoff, Adam Mccluskey
2002Garg MB, Sevester JC, Sakoff JA, Ackland SP, 'Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity', JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 774 223-230 (2002)
DOI10.1016/S1570-0232(02)00239-8Author URL
CitationsScopus - 35Web of Science - 30
Co-authorsJennette Sakoff
2002Garg MB, Sevester JC, Sakoff JA, Ackland S, 'Rapid and simple chromatographic method for the determination of uracil and dihydrouracil plasma levels: A potential pretreatment predictor of 5FU toxicity', Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Science, 774 223-230 (2002) [C1]
2002Sakoff J, De Waal E, Garg M, Denham J, Scorgie F, Enno A, et al., 'Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood', Leukemia and Lymphoma, 43(10) 2017-2020 (2002) [C1]
CitationsScopus - 21Web of Science - 22
Co-authorsLisa Lincz, Jennette Sakoff
2002Marx G, Lewis C, Hall K, Levi J, Ackland S, 'Phase I study of docetaxel plus ifosfamide in patients with advanced cancer', British Journal of Cancer, 87 846-849 (2002) [C1]
CitationsWeb of Science - 4
2002Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, et al., 'Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines', British Journal of Cancer, 86 1367-1372 (2002) [C1]
CitationsWeb of Science - 118
2001Ackland S, Anton A, Breitbach G, Colajori E, Tursi J, Delfino C, et al., 'Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophoshamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study', Journal of Clinical Oncology, 19 943-953 (2001) [C1]
CitationsScopus - 36Web of Science - 31
2001McCluskey A, Walkom CC, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters, 11 2941-2946 (2001) [C1]
CitationsScopus - 55Web of Science - 55
Co-authorsAdam Mccluskey, Michael Bowyer, Jennette Sakoff
2000Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al., 'Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.', NEW ENGLAND JOURNAL OF MEDICINE, 343 905-914 (2000)
DOI10.1056/NEJM200009283431302Author URL
CitationsScopus - 2372Web of Science - 1970
2000Peters G, De Bruin M, Fukushima M, Van Triest B, Hoekman K, Pinedo H, Ackland S, 'Thymidine phosphorylase in angiogenesis and drug resistance', Advances in Experimental Medicine and Biology, 486 291-294 (2000) [C2]
2000Peters GJ, van der Wilt CL, van Moorsel CJA, Kroep JR, Bergman AM, Ackland SP, 'Basis for effective combination cancer chemotherapy with antimetabolites', PHARMACOLOGY & THERAPEUTICS, 87 227-253 (2000)
DOI10.1016/S0163-7258(00)00086-3Author URL
CitationsScopus - 161Web of Science - 159
2000Sakoff J, Ackland S, 'Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells', Cancer Chemotherapy and Pharmacology, 46 477-487 (2000) [C1]
CitationsScopus - 29Web of Science - 26
Co-authorsJennette Sakoff
2000Garg M, Ackland S, 'Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine', Journal of Chromatography B, 748 383-388 (2000) [C1]
CitationsScopus - 47Web of Science - 46
2000Sakoff JA, McCluskey A, Sims ATR, Stewart JF, Ackland SP, 'A counter intuitive therapy for the treatment of cancer: Inhibition of protein phosphatases 1 and 2A by cantharidin (Spanish Fly) analogues.', CLINICAL CANCER RESEARCH, 6 4495S-4495S (2000)
Author URL
Co-authorsJennette Sakoff, Adam Mccluskey
1999Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al., 'Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer', Australasian Radiology, 43 220-226 (1999)

The purpose of the present paper was to evaluate treatment outcome after conservative breast surgery or mastectomy followed by simultaneous adjuvant radiotherapy and cyclophosphamide, methotrexate and fluorouracil (CMF) therapy. Two hundred and sixty eight (268) patients were treated at two Australian and two New Zealand centres between 1981 and July 1995. One hundred and sixty-nine patients underwent conservation surgery and 99 had mastectomies. Median follow-up was 53 months. Conventionally fractionated radiation was delivered simultaneously during the first two cycles of CMF, avoiding radiation on the Fridays that the intravenous components of CMF were delivered. In conservatively treated patients, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 34.5 ± 5.2%, 25.4 ± 4.5% and 75.5 ± 4.8%, respectively. Crude incidence of local relapse at 4 years was 6.3% and at regional/distant sites was 26.3%. Highest grades of granulocyte toxicity (< 0.5 x 109/L), moist desquamation, radiation pneumonitis and persistent breast oedema were recorded in 10.7, 8.5, 8.9 and 17.2%, respectively. In patients treated by mastectomy, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 59.7 ± 7.3%, 56.7 ± 7.4% and 50.1 ± 7%. The crude incidence of local relapse at 4 years was 5.6% and at regional/distant sites it was 45.7%. The issue of appropriate timing of adjuvant therapies has become particularly important with the increasing acknowledgement of the value of anthracycline-based regimens. For women in lower risk categories (e.g. 1-3 nodes positive or node negative), CMF may offer a potentially better therapy, particularly where breast-conserving surgical techniques have been used. In such cases CMF allows the simultaneous delivery of radiotherapy with the result of optimum local control, without compromise or regional or systemic relapse rates. Further randomized trials that directly address the optimal integration of the two modalities, such as the one carried out in Boston, are clearly necessary.

DOI10.1046/j.1440-1673.1999.00638.x
CitationsScopus - 12
1999Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P, Spry NA, 'Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy', EUROPEAN JOURNAL OF CANCER, 35 921-927 (1999)
DOI10.1016/S0959-8049(99)00065-9Author URL
CitationsScopus - 4Web of Science - 4
1999Ackland S, Rischin D, Beith J, Gupta S, Wyatt S, Davison J, et al., 'Phase I study of docetaxel epirubicin and cyclophosphamide (TEC) in patients with advanced cancer (AC)', EUROPEAN JOURNAL OF CANCER, 35 S292-S292 (1999)
DOI10.1016/S0959-8049(99)81594-9Author URL
1999Newell SA, Sanson-Fisher RW, Girgis A, Ackland S, 'The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study', European Journal of Cancer Care, 8 73-82 (1999) [C1]
CitationsScopus - 52Web of Science - 45
Co-authorsRob Sanson-Fisher
1999Ackland SP, Peters GJ, 'Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs', DRUG RESISTANCE UPDATES, 2 205-214 (1999)
DOI10.1054/drup.1999.0089Author URL
CitationsWeb of Science - 36
1998van der Heijden M, Ackland SP, Deveridge S, 'Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy - A case report and review of the literature', ACTA ONCOLOGICA, 37 107-109 (1998)
Author URL
CitationsScopus - 11Web of Science - 15
1998Ackland SP, 'Drug treatment of breast cancer', Australian Prescriber, 21 15-19 (1998)

The medical treatments available for breast cancer include endocrine agents, cytotoxic chemotherapy and adjunctive treatments. New antioestrogens and aromatase inhibitors offer a greater breadth of endocrine therapy and lower toxicity than some older drugs. Anthracyclines (doxorubicin or epirubicin) are now the major components of first-line combination chemotherapy. Many new cytotoxic drugs are currently undergoing phase III clinical trials and may ultimately find a role in the management of advanced disease, In adjuvant therapy of early breast cancer, either hormonal therapy, chemotherapy or both are needed to provide optimal reduction of the risk ofrecurrence.

1998Gurney HP, Ackland S, Gebski V, Farrell G, 'Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation', JOURNAL OF CLINICAL ONCOLOGY, 16 2299-2304 (1998)
Author URL
CitationsScopus - 88Web of Science - 80
1998Garg M, Ackland S, 'A sensitive method for the determination of docetaxel (Taxotere (R)) in human plasma by high performance liquid chromatography', ANNALS OF ONCOLOGY, 9 94-94 (1998)
Author URL
1998Ackland S, Garg M, van Moorsel CJA, Kuiper CM, Smid K, Peters GJ, 'Tomudex and cisplatin have additive cytotoxicity and no biochemical interaction in ovarian cancer cell lines', ANNALS OF ONCOLOGY, 9 155-155 (1998)
Author URL
1998Clarke S, Millward M, Findlay M, Ackland S, Hosie D, Abratt R, Goedhals L, 'Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC)', ANNALS OF ONCOLOGY, 9 86-87 (1998)
Author URL
CitationsWeb of Science - 13
1998van Laar JAM, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ, 'Comparison of 5-fluoro-2 '-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer', EUROPEAN JOURNAL OF CANCER, 34 296-306 (1998)
DOI10.1016/S0959-8049(97)00366-3Author URL
CitationsScopus - 74Web of Science - 68
1997Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, et al., 'A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: Preliminary results', SEMINARS IN ONCOLOGY, 24 5-9 (1997)
Author URL
CitationsWeb of Science - 2
1997Ackland SP, Garg MB, Dunstan RH, 'Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography', ANALYTICAL BIOCHEMISTRY, 246 79-85 (1997)
DOI10.1006/abio.1996.9943Author URL
CitationsScopus - 34Web of Science - 33
Co-authorsHugh Dunstan
1997Leong DCS, Kinlay S, Ackland S, Bonaventura A, Stewart JF, 'Low-risk febrile neutropenia in a medical oncology unit', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 27 403-407 (1997)
DOI10.1111/j.1445-5994.1997.tb02199.xAuthor URL
CitationsScopus - 11Web of Science - 6
1997Liu JP, Yajima Y, Li H, Ackland S, Akita Y, Stewart J, Kawashima S, 'Molecular interactions between dynamin and G-protein beta gamma-subunits in neuroendocrine cells', MOLECULAR AND CELLULAR ENDOCRINOLOGY, 132 61-71 (1997)
DOI10.1016/S0303-7207(97)00120-2Author URL
CitationsScopus - 18Web of Science - 19
1997Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, et al., 'Paclitaxel as first-line treatment for metastatic breast cancer', ONCOLOGY, 11 19-23 (1997)

When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to compare paclitaxel with standard chemotherapy as front-line therapy for this disease. Patients with measurable or evaluable metastatic breast cancer, no prior chemotherapy for metastatic disease, and an Eastern Cooperative Oncology Group performance status of 0 to 2 were randomized to receive paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles (6 months) or standard treatment with oral cyclophosphamide (Cytoxan) 100 mg/m2/d days 1 through 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5-fluorouracil 600 mg/m2 days 1 and 8, and oral prednisolone 40 mg/m2/d (CMFP) days 1 through 14 for six cycles (6 months). Patients whose disease progressed or relapsed were recommended to receive second-line epirubicin. Accrual has been completed with 208 patients randomized, but a preplanned interim analysis of the first 100 patients is reported here. Analysis of quality of life, assessed by a linear analogue scale and overall quality of life indices, is ongoing. Objective response occurred in 31% (confidence interval, 19% to 45%) with paclitaxel and 35% (confidence interval, 22% to 51%) with CMFP with stable disease in an additional 33% and 29%, respectively. Median time to progression was 5.5 months for paclitaxel-treated patients and 6.4 months for those given CMFP, with median survival durations of 17.3 and 11.3 months, respectively. Grades 3 and 4 neutropenia occurred in 64% of patients treated with paclitaxel and in 63% treated with CMFP. However, febrile neutropenia was the primary reason for hospitalization in 1% of paclitaxel courses, compared with 8% of CMFP courses. Nine percent of the patients had major infections with CMFP, but none were seen with paclitaxel. Moderate or severe mucositis occurred in 13% of paclitaxel-treated and 27% of CMFP-treated patients. Alopecia and peripheral neuropathy were more common with paclitaxel Quality of life assessments in the first 100 patients suggest better overall results on paclitaxel treatment as compared with CMFP. Preliminary analyses suggest that single-agent paclitaxel is well tolerated and provides comparable control of metastatic cancer to CMFP combination therapy when used as front-line treatment.

CitationsScopus - 16
1996Peters GJ, Ackland SP, 'New antimetabolites in preclinical and clinical development', Expert Opinion on Investigational Drugs, 5 637-679 (1996)

A number of new antimetabolites successfully entered clinical practice over the last ten years, and several more are awaiting registration in a number of countries. In addition, several compounds have been developed for use in combination with established anticancer agents (primarily 5-fluorouracil [5-FU] or one of its analogues). The most successful group of new anticancer agents are the deoxynucleoside analogues (e.g., cladribine, fludarabine, 5-aza-2'-deoxycytidine and gemcitabine), which require activation by one of the four deoxynucleoside kinases present in mammalian cells. However, a further analogue, pentostatin, is a potent inhibitor of adenosine deaminase, leading to an increase in deoxyadenosine, which becomes toxic after conversion to the deoxynucleotide. Other interesting compounds require activation by a viral deoxynucleoside kinase; the Herpes Simplex Virus (HSV)-thymidine kinase (TK), e.g., ganciclovir. A number of compounds have been developed to modulate the activity of 5-FU, e.g., ethynyluracil (EU) and 5-chloro-2,4- dihydroxypyridine (CDHP) inhibit dihydropyrimidine dehydrogenase (DPD), thus, preventing degradation of 5-FU and increasing its bioavailability. Prodrugs of 5-FU have attracted much more attention recently than in the 1980s: e.g., ftorafur, present in (UFT) [1-(2-tetrahydrofuryl)-5-fluorouracil:uracil (1:4)] and S-1, and capecitabine, a prodrug of the 5-FU precursor 5'-deoxy-5- fluorouridine. Antifolates have also received a lot of attention and several new antifolates have been developed over the last ten years, of which the most interesting are the new thymidylate synthase (TS) inhibitors. Many of these have entered clinical development and some have even been registered (e.g., tomudex in England). These compounds include tomudex (ZD1694, formerly ICI-D1694; Zeneca), LY231514 (Eli Lilly), 1843U89 (formerly BW1843U89; Glaxo Wellcome), and AG331 and AG337 (Thymitaq; Agouron). AG337 is of special interest, since it appears to exhibit a different pattern of activity to that of tomudex. A new group of antifolates in development, and generating considerable interest, are the glycinamide ribonucleotide transferase (GARTF) inhibitors: e.g., lometrexol and LY309887 (Eli Lilly), and AG2032 and AG2034 (Agouron). However, the place of these compounds in therapy (i.e., as single agents or as modulating agents) remains unclear at present. In summary, rational drug design over the last few decades has led to the introduction of a number of antimetabolites with significant antitumour activity not only against leukaemia, but also against several solid tumours. © 1996 Ashley Publications Ltd.

DOI10.1517/13543784.5.6.637
CitationsScopus - 56
1995DENHAM JW, HAMILTON CS, CHRISTIE D, OBRIEN M, BONAVENTURA A, STEWART JF, et al., 'SIMULTANEOUS ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER - TOXICITY AND DOSE MODIFICATION - A TRANS-TASMAN RADIATION ONCOLOGY GROUP MULTI-INSTITUTION STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 31 305-313 (1995)
DOI10.1016/0360-3016(94)E0065-RAuthor URL
CitationsScopus - 28Web of Science - 23
1995BURMEISTER BH, DENHAM JW, OBRIEN M, JAMIESON GG, GILL PG, DEVITT P, et al., 'COMBINED-MODALITY THERAPY FOR ESOPHAGEAL-CARCINOMA - PRELIMINARY-RESULTS FROM A LARGE AUSTRALASIAN MULTICENTER STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32 997-1006 (1995)
DOI10.1016/0360-3016(94)00449-UAuthor URL
CitationsScopus - 50Web of Science - 44
1993Ackland SP, Hamilton CS, Joseph DJ, Denham JW, 'Phase I/II study of concurrent weekly carboplatin and radiation therapy in advanced head and neck cancer', Clinical Oncology, 5 133-138 (1993)

Thirty-two patients with locally advanced head and neck cancer have been treated with concurrent weekly carboplatin and conventional radiation therapy (RT) (2 Gy fractions 4-5 days/week to a total dose of 64-70 Gy over 7-8 weeks) in a Phase I/II study. Carboplatin was administered weekly during RT at doses of 75-150 mg/m2//wk as a 1-hour infusion. The maximum tolerated dose of carboplatin was 130 mg/m2//wk, with myelosuppression, predominantly neutropenia, being dose limiting. Other systemic toxicities were insignificant and no overlapping toxicity was evident. Ultimate locoregional control and survival probabilities were disappointing. It is suggested that either further studies using radiation and carboplatin at the dose 130 mg/m2//wk, or variations on dose and scheduling be performed prior to the instigation of Phase III studies. © 1993 The Royal College of Radiologists.

DOI10.1016/S0936-6555(05)80307-3
CitationsScopus - 4
1993Cooper SG, Bonaventura A, Ackland SP, Joseph DJ, Stewart JF, Hamilton CS, Denham JW, 'Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: A phase II study', Clinical Oncology, 5 169-173 (1993)

Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival. We wished to find out if we could safely give concurrent radiotherapy and 5-fluorouracil (5-FU) modulated by leucovorin (LV) in 3 settings: pre-operatively, adjuvantly and in recurrent disease. A total of 39 patients were treated, 11 preoper-atively, 17 adjuvantly and 11 with recurrent disease. There were 26 males and 13 females with a median age of 64 years. The median radiotherapy (RT) dose was 45 Gy/25 fractions/1.8 Gy per fraction (range 25-63 Gy). Chemotherapy consisted of LV 80 mg/m2 i.v. infusion over 1.5 hours followed by 5-FU 400 mg/m2 i.v. bolus, both given once a week. The median number of cycles was 8 (range 3-12). Diarrhoea was the main toxicity, and was encountered in 30 patients (77%): grade 1 in 3 (8%), grade 2 in 12 (30%), grade 3 in 11 (28%), and grade 4 in 4 (10%). This required 18 (46%) patients to have modifications to their RT (20% had breaks and 26% ceased at doses <45 Gy). Nine patients (23%) had modifications in the chemotherapy (10% had breaks and 13% received <6 cycles). Encouraging responses were seen in the preoperative setting. Concurrent RT and 5-FU/LV, as given in this schedule, results in an unacceptable incidence of diarrhoea, limiting both the total dose of RT and chemotherapy that can be delivered, particulary in patients who have had previous surgery. © 1993 The Royal College of Radiologists.

DOI10.1016/S0936-6555(05)80319-X
CitationsScopus - 12
1990JOSEPH DJ, HAMILTON CS, DENHAM JW, ACKLAND SP, STEWART JF, 'WHITHER SCREENING MAMMOGRAPHY IN AUSTRALIA - ESTABLISHING A SATISFACTORY BASIS FOR FUNDING', MEDICAL JOURNAL OF AUSTRALIA, 152 545-546 (1990)
Author URL
1989COOPER SG, DENHAM JW, HAMILTON CS, JOSEPH DJ, STEWART JF, ACKLAND SP, 'THE PRICE OF A FALSE-NEGATIVE RESULT OF MAMMOGRAPHY AND AN OVERENTHUSIASTIC LAY PRESS', MEDICAL JOURNAL OF AUSTRALIA, 150 664-664 (1989)
Author URL
CitationsWeb of Science - 1
Show 90 more journal articles

Conference (35 outputs)

YearCitationAltmetricsLink
2014Bryant J, Sanson-Fisher R, Fradgley L, Regan T, Hobden B, Ackland S, Turon H, 'ONCOLOGY PATIENTS OVERWHELMINGLY SUPPORT TISSUE BANKING', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsRob Sanson-Fisher
2014Baylock B, Dhillon HM, Courneya K, O'Callaghan C, O'Brien A, Goddard AM, et al., 'A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH HIGH-RISK STAGE II OR STAGE III COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (NCIC CTG CO.21)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
2014Baylock B, Dhillon HM, Goddard EM, Turner J, Rice H, Kabourakis M, et al., 'THE COLON HEALTH AND LIFE-LONG EXERCISE CHANGE (CHALLENGE) TRIAL: PARTICIPANT ADHERENCE TO FITNESS ASSESSMENTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
2014Ackland SP, Zdenkowski N, Adler K, Hall S, Jones D, 'MIDKINE AS A PREDICTIVE MARKER IN METASTATIC COLORECTAL CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsSharron Hall
2014Ackland SP, Scott RJ, Moscato P, Ovchinkova L, 'A PLATFORM FOR PHARMACOGENOMIC ANALYSIS OF ADVERSE DRUG REACTIONS IN CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsPablo Moscato, Rodney Scott
2014Agrez M, Garg MB, Parker S, Ackland SP, 'DEVELOPMENT OF INTEGRIN-DERIVED PEPTIDE-BASED ANTICANCER COMPOUNDS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
2014Garg MB, Sakoff JA, Johnson C, Bonaventura A, Ackland SP, 'CLINICAL STUDY OF MITOTANE PHARMACODYNAMICS IN ADRENOCORTICAL CANCER IN CHILDREN AND ADULTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsJennette Sakoff
2014Prawira A, Garg MB, Sakoff JA, Lincz LF, Adler K, Scorgie FE, Ackland SP, 'FACTORS PREDICTING RESPONSE AND SURVIVAL IN COLORECTAL CANCER PATIENTS RECEIVING ADJUVANT 5-FLUOROURACIL CHEMOTHERAPY: 10-YEAR FOLLOW-UP OF A PROSPECTIVE PATIENT COHORT', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsLisa Lincz, Jennette Sakoff
2014Guo ST, Chi MN, Yang RH, Guo XY, Wang CY, Zan LQ, et al., 'INOSITOL POLYPHOSPHATE 4-PHOSPHATASE II PROMOTES PI3K SIGNALING AND FUNCTIONS AS AN ONCOGENIC REGULATOR IN HUMAN COLON CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsXu Zhang, Rick Thorne, Rodney Scott
2013Girgis A, Bonaventura T, Bonevski B, Hogan M, Boyes A, Proietto T, et al., 'FEASIBILITY STUDY OF AN ONCOLOGY NURSE PRACTITIONER MODEL OF CARE IN A RURAL CANCER SETTING', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2013) [E3]
Author URL
Co-authorsAllison Boyes, Billie Bonevski
2012Upanal NN, Ackland SP, Bonaventura A, McElduff P, 'Early rise in blood pressure to predict clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with first-line bevacizumab', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2012) [E3]
Author URL
2012Sakoff JA, Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, 'Predicting chemotherapy-induced toxicity in cancer patients from peripheral blood telomere length', European Journal of Cancer, Barcelona, Spain (2012) [E3]
Co-authorsJennette Sakoff, Lisa Lincz
2012Goddard EM, Dhillon HM, Turner J, Kabourakis M, Beale PJ, Goodwin A, et al., 'The impact of physical activity on disease-free survival in patients with high-risk stage II or III colon cancer: One month screening results', Asia-Pacific Journal of Clinical Oncology, Brisbane (2012) [E3]
2012Upanal NN, Ackland S, Bonaventura A, McElduff P, 'Improved clinical outcomes in metastatic colorectal cancer patients on first-line chemotherapy with bevacizumab can be predicted by early rise in blood pressure', Asia-Pacific Journal of Clinical Oncology, Brisbane, Queensland (2012) [E3]
2011Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al., 'Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)', JOURNAL OF CLINICAL ONCOLOGY (2011)
Author URL
2010Garg M, Sakoff JA, Ackland S, 'A simple HPLC method to measure plasma mitotane and its two main metabolites in adrenocortical cancer patients', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsJennette Sakoff
2010Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Telomere length in peripheral blood mononuclear cells (PBMNC) predicts for leukopenia, neutropenia and mucositis in colorectal cancer patients treated with 5FU', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsLisa Lincz, Jennette Sakoff
2010Ackland S, 'Challenges in clinical trials design and management in the 21st century', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2010Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Short telomeres in PBMNC predicts for haematological toxicity in colorectal cancer patients treated with 5FU', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authorsJennette Sakoff, Lisa Lincz
2010Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B, Ackland SP, et al., 'A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS)', JOURNAL OF CLINICAL ONCOLOGY (2010)
Author URL
CitationsWeb of Science - 10
2009Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, et al., 'GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC)', JOURNAL OF CLINICAL ONCOLOGY, Orlando, FL (2009) [E3]
Author URL
CitationsWeb of Science - 2
2007Sobrero A, Young S, Balcewicz M, Chiara S, Perez-Carrion R, Mainwaring P, et al., 'A large phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in metastatic CRC: AVIRI', Annals of Oncology, Barcelona, Spain (2007) [E3]
2007Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, et al., 'Final data from a large phase II trial of first-line bevacizurnab plus classic or modified FOLFIRI in metastatic colorectal cancer (CRC)', European Journal of Cancer Supplements, Barcelona, Spain (2007) [E3]
CitationsWeb of Science - 1
2007Ngan S, Fisher R, Mackay J, Solomon M, Burmeister B, Goldstein D, et al., 'Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04)', European Journal of Cancer Supplements, Barcelona, Spain (2007) [E3]
CitationsWeb of Science - 5
2007Ackland S, Dhillon H, Jakob L, 'The COSA and Cooperative Groups Enabling Project: What is intended to be accomplished', Asia Pacific Journal of Clinical Oncology, Adelaide, SA (2007) [E3]
2007Ackland S, Dhillon H, 'Improving processes across all Cancer Cooperative Trials Groups through Standard Operating Procedures (SOPS)', Asia Pacific Journal of Clinical Oncology, Adelaide, SA (2007) [E3]
2006Stockler MR, Sourjina T, Harvey V, Frances P, Byrne M, van Hazel G, et al., 'A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment.', BREAST CANCER RESEARCH AND TREATMENT, San Antonio, TX (2006)
Author URL
CitationsWeb of Science - 7
Co-authorsJohn Forbes
2006Sobrero A, Ackland S, Carrion RP, Chiara S, Clarke S, Giron CG, et al., 'Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.', JOURNAL OF CLINICAL ONCOLOGY, Atlanta, GA (2006)
Author URL
CitationsWeb of Science - 5
2006Sobrero A, Ackland S, Perez Carrion R, Chiara S, Clarke S, Garcia Giron C, et al., 'First-line bevacizumab plus infusional 5-FU/irinotecan in metastatic CRC: Initial data from the AVIRI trial', ANNALS OF ONCOLOGY, Barcelona, SPAIN (2006)
Author URL
2006Sobrero A, Ackland S, Carrion RP, Chiarra S, Clarke S, Giron CG, et al., 'Aviri, a large phase II trial of first-line bevacizumab plus infusional 5-FU/leucovorin and irinotecan (FOLFIRI) in metastatic CRC', ANNALS OF ONCOLOGY, Istanbul, TURKEY (2006)
Author URL
2006Girgis A, Boyes AW, Clinton-Mcharg T, Ackland S, Pr H, 'Proactive, routine monitoring and intervention to reduce the psychosocial impact of cancer and its treatment in outpatient oncology services', Psycho-Oncology:Journal of the psychological, social and behavioral dimension of cancer, Ferrara-Venice, Italy (2006) [E3]
Co-authorsAllison Boyes
2004Kacen L, Madjar I, Denham J, Ackland S, Aried S, 'The patient-other dynamics of the decision to forgo or stop active treatment for cancer', Palliative Medicine, Stresa, Italy (2004) [E3]
2003Smithers BM, Burmeister BH, Fitzgerald L, Gebski V, Denham J, Devitt P, et al., 'A randomized controlled trial of surgery alone compared with chemoradiation & surgery: a focus on the surgical outcomes', ANNALS OF SURGICAL ONCOLOGY, LOS ANGELES, CALIFORNIA (2003)
Author URL
CitationsWeb of Science - 3
2002Sakoff JA, Ackland SP, Garg MB, Walkom CC, McCluskey A, 'Protein phosphatase 2A, a novel and unexplored anticancer target', EUROPEAN JOURNAL OF CANCER, FRANKFURT, GERMANY (2002)
Author URL
Co-authorsJennette Sakoff, Adam Mccluskey
2001Keath R, Stewart J, Ackland S, Bonaventura A, 'Guidelines for the use of colony stimulating factors in patients receiving adjuvant chemotherapy for breast cancer', Proceedings in European Journal of Cancer, Unknown (2001) [E3]
Show 32 more conferences
Edit

Grants and Funding

Summary

Number of grants28
Total funding$12,057,876

Click on a grant title below to expand the full details for that specific grant.


20145 grants / $666,562

Sub-Project - Hunter Cancer Research Alliance; HCRA$285,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamConjoint Professor Stephen Ackland
SchemeTranslational Cancer Research Centre Grants
RoleLead
Funding Start2014
Funding Finish2014
GNoGS140009
Type Of FundingOther Public Sector - State
Category2OPS
UONY

High Throughput Image Capture Platform for Translational Cancer Research$282,614

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamConjoint Professor Stephen Ackland, Professor Rodney Scott, Professor John Forbes, Professor Xu Dong Zhang, Professor Marjorie Walker, Professor Hubert Hondermarck, Doctor Craig Gedye, Doctor Rick Thorne, Mr Loui Rassam, Doctor Stephen Braye
SchemeResearch Equipment Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1400626
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Biobanking Stakeholder Network Pre-Operative Consent Project$55,580

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamProfessor Rodney Scott, Conjoint Professor Stephen Ackland
SchemeCommunity of Practice Program
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301060
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Circulating microRNAs and RNAs as biomarkers of response and toxicity to chemoradiotherapy for oesophageal cancer$22,500

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Xu Dong Zhang, Conjoint Professor Stephen Ackland
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1401397
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

ProBBANG: Prospective study of Bevacizumab-induced Blood pressure and ANGiogenic factors as predictive biomarkers in colorectal cancer$20,868

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Stephen Ackland
SchemeProject Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1301365
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20132 grants / $1,091,860

HMRI MRSP Infrastructure (12-16) – CANCER $991,860

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Stephen Ackland
SchemeNSW MRSP Infrastructure Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1300588
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Investigation into a collaborative imaging database for NSW biobanks.$100,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamProfessor Rodney Scott, Conjoint Professor Stephen Ackland, Assoc. Prof Nicholas Hawkins, Associate Professor Deborah Marsh
SchemeCommunity of Practice Program
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1300902
Type Of FundingOther Public Sector - State
Category2OPS
UONY

20123 grants / $455,694

High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Emeritus Professor Leonie Ashman
SchemeProject Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1200555
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Mitotane pharmacodynamics in Adrenocortical Cancer in children and adults $20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Stephen Ackland, Doctor Jennette Sakoff, Ms MADHU Garg
SchemeProject Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200319
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20112 grants / $2,189,263

Hunter Translational Cancer Research Unit$1,693,333

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamConjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Laureate Professor Robert Sanson-Fisher, Conjoint Associate Professor Anthony Proietto, Professor Rodney Scott
SchemeTranslational Cancer Research Unit
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100545
Type Of FundingOther Public Sector - State
Category2OPS
UONY

HMRI MRSP Infrastructure (11-12)-Cancer $495,930

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Stephen Ackland
SchemeNSW MRSP Infrastructure Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1101207
Type Of FundingOther Public Sector - State
Category2OPS
UONY

20102 grants / $1,061,705

Feasibility study of an oncology nurse practitioner model of care at improving outcomes in a rural cancer setting$557,634

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamConjoint Professor Afaf Girgis, Conjoint Associate Professor Anthony Proietto, Associate Professor Billie Bonevski, Doctor Allison Boyes, Conjoint Professor Stephen Ackland, Doctor Anthony Bonaventura, Mr Douglas Bellamy
SchemeTranslational Health Service Research Grant
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG0190563
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

HMRI MRSP Infrastructure Grant (10-11) - CANCER$504,071

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamEmeritus Professor Leonie Ashman, Conjoint Professor Stephen Ackland
SchemeNSW MRSP Infrastructure Grant
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG1100269
Type Of FundingOther Public Sector - State
Category2OPS
UONY

20092 grants / $613,916

Provision of non-physical infrastructure support to enhance the breast cancer clinical trials research activities of the ANZ BCTG and its ability to build productive research collaborations$330,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamProfessor John Forbes, Associate Professor Frances Boyle, Conjoint Professor Stephen Ackland, Professor Alan Coates
SchemeResearch Infrastructure Grants
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0190219
Type Of FundingOther Public Sector - State
Category2OPS
UONY

MRSP Infrastructure (09-10) Cancer$283,916

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamEmeritus Professor Leonie Ashman, Conjoint Professor Stephen Ackland
SchemeNSW MRSP Infrastructure Grant
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0900172
Type Of FundingOther Public Sector - State
Category2OPS
UONY

20082 grants / $1,191,290

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
SchemeNSW MRSP Infrastructure Grant
RoleLead
Funding Start2008
Funding Finish2008
GNoG0188622
Type Of FundingOther Public Sector - State
Category2OPS
UONY

HMRI Senior Research Fellow$160,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor John Attia, Emeritus Professor Maree Gleeson, Professor Rodney Scott, Conjoint Professor Vaughan Carr, Conjoint Professor Stephen Ackland, Professor Michael Hazelton, Professor Trevor Day
SchemeSenior Fellowship
RoleInvestigator
Funding Start2008
Funding Finish2008
GNoG0188558
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20071 grants / $12,214

(102) Hunter Medical Research Institute - Cancer$12,214

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamConjoint Professor Stephen Ackland
SchemePublication Performance Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187977
Type Of FundingInternal
CategoryINTE
UONY

20061 grants / $621,143

20053 grants / $3,677,564

Protocol development, web-based data collection and date quality assurance for all Cancer Cooperative Trials Groups$1,840,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamConjoint Professor Stephen Ackland, Professor Alan Coates, Professor John Zalcberg, Professor Max Wolf, Dr Kwun Fong, Professor John Forbes, Dr Helen Irving, Dr Guy Toner, Professor Michael Friedlander, Professor John Thompson, Dr David Ball, Professor John Simes
SchemeEnabling Grants - Clinical Trials Resources
RoleLead
Funding Start2005
Funding Finish2005
GNoG0184628
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

Enhancement of the ANZBCTG research program through the provision of infrastructure funding for essential management and operational personnel and other key activities $1,720,564

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamProfessor John Forbes, Professor Alan Coates, Professor John Simes, Conjoint Professor Stephen Ackland
SchemeResearch Infrastructure Grants
RoleInvestigator
Funding Start2005
Funding Finish2005
GNoG0185068
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Proactive monitoring and intervention to reduce the pyschosocial impact of cancer therapy$117,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamConjoint Professor Afaf Girgis, Doctor Allison Boyes, Conjoint Professor Stephen Ackland
SchemeResearch Infrastructure Grants
RoleInvestigator
Funding Start2005
Funding Finish2005
GNoG0185057
Type Of FundingNot Known
CategoryUNKN
UONY

20021 grants / $10,000

New targets for chemotherapy: anti-cancer drugs that target protein phosphatases$10,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff
SchemeProject Grant
RoleInvestigator
Funding Start2002
Funding Finish2002
GNoG0181459
Type Of FundingInternal
CategoryINTE
UONY

20012 grants / $431,665

Investigations into the biological functioning and prognostic value of novel metastatic marker for breast cancer.$420,665

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Gordon Burns, Conjoint Professor Anthony Leong, Conjoint Professor Stephen Ackland
SchemeProject Grant
RoleInvestigator
Funding Start2001
Funding Finish2001
GNoG0179658
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Using Genetics and Pharmacokinetics to Predict Toxicity of Chemotherapy.$11,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamConjoint Professor Stephen Ackland
SchemeProject Grant
RoleLead
Funding Start2001
Funding Finish2001
GNoG0180063
Type Of FundingInternal
CategoryINTE
UONY

20001 grants / $10,000

Pre-treatment Uracil: Dihydrouacil Ratio as a Predictor of 5FU Pharmacokinetics and Myelotoxicity of Chemotherapy.$10,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamConjoint Professor Stephen Ackland
SchemeSmall Grant
RoleLead
Funding Start2000
Funding Finish2000
GNoG0178977
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

19991 grants / $25,000

Selective Inhibitors of Protein Phosphatases as Anti-cancer agents$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff, Professor Adam McCluskey, Conjoint Professor Stephen Ackland
SchemeResearch Grant
RoleInvestigator
Funding Start1999
Funding Finish1999
GNoG0178390
Type Of FundingContract - Aust Non Government
Category3AFC
UONY
Edit

Research Supervision

Past Supervision

YearResearch Title / Program / Supervisor Type
2007The Patterns of Care for Patients with Lung Cancer in the Hunter Region, Australia (1996-2002)
General Medicine, Faculty of Health and Medicine
Co-Supervisor
2001Predicting myelotoxicity of 5-FU chemotherapy.
Biol Sc Not Elsewhere Classifd, University of Newcastle
Co-Supervisor
2000Influence of telomere length and telomerase activity in bone marrow progenitor cells on the time required to fully regenerate the bone marrow after an autologous peripheral blood stem cell transplantation.
Biol Sc Not Elsewhere Classifd, University of Newcastle
Co-Supervisor
Edit

News

Cancer Boost

Major cancer boost

June 3, 2014

The Hunter Cancer Research Alliance (HCRA) has become the first regionally based organisation to receive full Translational Cancer Research Centre status and an accompanying $6.5-million funding injection from the Cancer Institute NSW.

Cancer Genome Atlas

Cancer Genome Atlas

July 17, 2013

Scientists and clinicians aim to foster targeted approach to cancer treatment by improving communication channels.

 

Conjoint Professor Stephen Ackland

Position

Conjoint Professor
Medical Oncology
Faculty of Health and Medicine

Focus area

Pharmacy and Experimental Pharmacology

Contact Details

Emailstephen.ackland@newcastle.edu.au
Phone(02) 4014 3570
Mobile0408 492868
Fax(02) 4968 0384

Office

RoomNM2
BuildingMater Hospital Level 3 - New Med 2
LocationOther

,
Edit